Back to Search
Start Over
Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial
- Source :
- Plus Company Updates. June 25, 2020
- Publication Year :
- 2020
-
Abstract
- Cambridge: AstraZeneca PLC (AZNCF) has issued the following press release: Full results from the positive Phase III ETHOS trial showed AstraZeneca's triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.627668556